Therapeutic drug monitoring and virological response at week 48 in a cohort of HIV-1 infected-patients switching to dolutegravir/rilpivirine dual maintenance therapy (ANRS-MIE-BIRIDER Study).
Florian LemaitreJennifer Lagoutte-RenosiMarie-Claude GagnieuFrançois ParantNicolas VenisseMatthieu GregoireStéphane BouchetRodolphe GarraffoMinh Patrick LêPatrice MuretEmmanuelle CometsCaroline SolasGilles Peytavinnull nullPublished in: British journal of clinical pharmacology (2023)
A majority of PLWHA receiving DTG/RPV maintenance dual therapy demonstrated VL<50 cp/mL but virological replication was more frequent in people living with HIV/AIDS with subtherapeutic Cmin.